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See Article, pages 475–482Acute deterioration in the clinical condition of a cir-
rhotic patient due to the eﬀects of a precipitating illness
leading to hospital admission is associated with widely
variable clinical outcomes. A proportion of patients
makes an appropriate response to treatment of the pre-
cipitating event and can be discharged relatively quickly
from hospital. There are a second group of patients,
who despite treatment of the precipitating event pro-
gress to organ dysfunction, developing complications
of cirrhosis and this is the group that is associated with
high mortality rates and is referred to broadly as ‘Acute
on Chronic Liver Failure’ (ACLF) [1]. The underlying
mechanisms that determine which patient will recover
and which patient will progress to multiple organ dys-
function despite similar precipitating events is not clear.
The paper by Cazzaniga et al. in the present issue of the
Journal addresses this important question and suggests
that a systemic inﬂammatory response may be impor-
tant in determining outcomes [2].Multi-organ failure in cirrhosis
The term ACLF is not well deﬁned but the syndrome
it describes is known to all hepatologists [1]. ACLF
refers to an acute deterioration in liver function in a
patient with previously stable cirrhosis which results in
‘organ failure’ most commonly hepatic encephalopathy
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ondary. The primary insult can be due to the direct
eﬀects of a hepatotoxic factor including hepatotrophic
viruses, a drug reaction or ingestion of hepatotoxins
such as alcohol. Alternatively, the liver insult may be
indirect as is seen in sepsis, in which case it is secondary
end organ damage aﬀecting the liver [3].
The underlying central theme in multi-organ dysfunc-
tion of cirrhosis is a profound disturbance in systemic
hemodynamics. The cirrhotic patient has an increased
or decreased cardiac output and a dilated, hyporespon-
sive peripheral circulation. There is increased portosys-
temic shunting, portal pressure with a reduction in
renal blood ﬂow [4]. The involvement of nitric oxide, a
profound vasodilator, has gained considerable interest
as an important mediator in this process [5]. In addition,
to these systemic changes there are microvascular
changes aﬀecting capillary beds including disseminated
intravascular coagulation. The acute hepatic insult in
cirrhosis patients produces a pro-inﬂammatory milieu
that exacerbates the circulatory changes seen in cirrhosis
resulting in inadequate tissue perfusion and multi-organ
failure. Hence, it has been shown that liver function is
not the main determinant of outcome in cirrhotic
patients with multi-organ dysfunction, thus the classical
scores of hepatic function (Childs Pugh/MELD) are not
able to accurately predict survival. Organ failure scores
such as APACHE 11 and SOFA are more helpful in pre-
dicting outcome as was also shown by Cazzaniga [1,3,
6–8].The role of the systemic inﬂammatory response (Fig. 1)
The important role of the systemic inﬂammatory
response (SIRS), which is a conglomeration of veryPublished by Elsevier B.V. All rights reserved.
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Fig. 1. This ﬁgure illustrates the possible outcomes of a patient with
cirrhosis who is admitted to the hospital depending upon the occurrence
and/or resolution of a systemic inﬂammatory response. In the patients in
whom the systemic inﬂammatory response persists, it is likely they will
progress to the organ injury/immune dysfunction pathway leading to a
high probability of developing acute on chronic liver failure with a self-
perpetuating vicious cycle. [This ﬁgure appears in colour on the web.]
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measure using heart and respiratory rates, temperature
and white cell count, in determining the outcome of
patients with liver failure was ﬁrst fully described in
the acute liver failure patient population, where the pres-
ence of SIRS, was associated with more severe encepha-
lopathy, associated infection, renal failure and poor
outcome [9–11]. More recently, the mortality of patients
presenting with renal dysfunction of cirrhosis was signif-
icantly higher in the group with SIRS [12,13]. The study
by Cazzaniga and colleagues conﬁrms and extends these
data in 141 patients with cirrhosis [2]. The group shows
the presence of SIRS predicts a poor outcome in
patients with cirrhosis presenting to the hospital with
an episode of decompensation. The initial level of the
SIRS response and persistent presence of SIRS during
hospital stay have also been shown to be independent
predictors of poor outcome in other studies [3,6–8].
The study by Cazzaniga et al. [2] does not throw light
on the mechanisms of this inﬂammatory response or the
mechanism of how SIRS leads to increased multi-organ
dysfunction and exacerbated mortality. Studies in our
group have focused on this question and we have
observed evidence of severe hemodynamic derange-
ments manifested by accentuation of the severity of por-
tal hypertension and reduction in hepatic blood ﬂow
when there is superimposed inﬂammatory stress on the
background of existing cirrhosis [14]. We observed that
this was associated with an increase in the concentration
asymmetric dimethylarginine, which is an endogenous
inhibitor of nitric oxide synthase [4,15]. The role of
SIRS in the development of renal failure of cirrhosis
can be explained by a shift in the renal autoregulation
curve towards the left as shown recently [16]. Infec-
tion/inﬂammation is a well-known precipitant of hepatic
encephalopathy in cirrhotic patients [17]. Recent studies
in experimental models suggest that inﬂammation may
alter cerebral blood ﬂow [18], increase peroxynitrite for-
mation and also lead to activation of inﬂammatory
response in the brain [19,20]. More recently, patients
with SIRS on the background of cirrhosis have been
shown to have a marked reduction in the functional
capacity of the circulating albumin with evidence of oxi-
dative modiﬁcation of albumin [21]. The question of the
mechanism of whether cirrhosis predisposes to the
eﬀects of the precipitating illness and in some ways exac-
erbates the inﬂammatory response is unclear.Inﬂammation and infection
From the pathophysiological perspective, it is
expected that SIRS should be associated with increased
pro-inﬂammatory cytokine response and possibly posi-
tive clinical outcomes with the use of anti-inﬂammatory
interventions. This is clearly not the case with verywidely variable values in the literature [22] for the
measured cytokines and the observation that use of
anti-TNF alpha strategies in the patients with severe
alcoholic hepatitis who are deﬁned by SIRS, was associ-
ated with increased risk of infection and poorer outcome
in the treated group compared with the placebo treated
group [23,24]. However, the use of anti-TNF antibodies
in these patients was associated with an immediate and
sustained improvement in the hemodynamic status with
a reduction in portal pressure, and an increase in hepatic
and renal blood ﬂow highlighting that in principle, inter-
ventions dealing with SIRS have the potential to be
eﬀective [4]. However, the limiting factor to using any
intervention that has the potential to further reduce
the function of the immune system is likely to be delete-
rious. This is well illustrated in the Cazzaniga study,
where 57% of patients with SIRS had associated
infection.
It is likely that it is not necessarily the SIRS itself but
the cause of a SIRS response that may be important.
This hypothesis is highlighted by the observation that
the outcome in patients with decompensated alcoholic
cirrhosis was better when the precipitating event was
superimposed alcoholic hepatitis rather than sepsis
[25]. In fact, bacterial infection is the major cause of
death in patients with decompensated cirrhosis. The
cyclical relationship between the SIRS response and
infection cannot be overstated and appears to be central
to the pathophysiology of the condition [8]. A SIRS
response leads to immune deregulation predisposing to
infection, whilst at the same time infection initiates a
pro-inﬂammatory response resulting in SIRS. This
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been the subject of a recent study from our group where
we explored neutrophil function in patients with severe
alcoholic hepatitis. In patients with marked SIRS, circu-
lating neutrophils were undergoing spontaneous respira-
tory burst but these neutrophils had lost the ability to
perform phagocytic function. The severity of these func-
tional abnormalities was predictive of ‘new’ infection
and subsequent mortality [26]. Furthermore, we were
able to show that this defect was the result of a humoral
factor, most likely to be endotoxin-like substance acting
through a toll-like receptor pathway [26]. These obser-
vations provide novel ideas to determine which patients
are likely to be at risk of subsequent infection and
should be targets for intensive monitoring and
treatment.Future directions
The best recognized determinant of outcome in
patients with cirrhosis who present with an acute deteri-
oration is organ failure [1–3,6,7]. Interestingly, Cazzan-
iga and colleagues have demonstrated that SIRS
predicts portal hypertension-related bleeding, hepatic
encephalopathy and hepatorenal syndrome in a signiﬁ-
cant proportion of patients with cirrhosis, resulting in
increased mortality. The development of 1, 2 or 3 organ
system failures is associated with a high mortality of
21%, 55% or 100%, respectively, making ACLF an
important condition to identify early and treat [1–
3,6,7,27]. Importantly, early aggressive goal directed
therapy has been shown in other situations such as sep-
sis to improve outcome. In addition, it should be recog-
nised that the selection and timing of liver support
therapies and liver transplantation is critical to the opti-
mal management of a proportion of patients.
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